- Oral presentation
- Open Access
- Jeff Elias1
© Elias; licensee BioMed Central Ltd. 2015
- Published: 30 June 2015
- Public Health
- Clinical Trial
- Disease Rating
- Motor Symptom
- Cognitive Assessment
A clinical trial is being planned to investigate the management of medication-refractory motor symptoms associated with Parkinson’s disease using a unilateral, focused ultrasound subthalamotomy performed in a staged fashion.
For this study, ten subjects with medication-refractory symptoms or side effects of advanced Parkinson’s disease will be enrolled. Each patient will be treated with a “sub-therapeutic” (stage 1) focused ultrasound subthalamotomy and observed for thirty days.
Those who develop severe and involuntary movements, such as hemiballismus, will be excluded from the second stage procedure. For those who tolerate subthreshold lesioning, a second, full subthalamotomy ablation (stage 2) with focused ultrasound will be performed. Validated Parkinson’s disease rating scales, cognitive assessments, and MRI will be obtained before and after the procedures.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.